This year has been notable for initial public offerings (IPOs), with Cerebras Systems hosting the largest yet and SpaceX preparing to launch an even bigger one. Additionally, biotech is thriving, highlighted by Parabilis Medicines’ recent IPO, which raised $670 million and saw its stock surge 58% on the first trading day. Parabilis, focused on treating “undruggable” cancers with its novel Helicon platform, plans to enter phase 3 trials for its lead candidate, zolucatetide. While the technology shows promise, the company’s deepening losses make it a riskier investment, appealing mainly to aggressive investors with a long-term outlook.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/markets/stocks/articles/parabilis-soared-58-biggest-biotech-065000933.html
